(Reuters) - ZURICH, April 18 - Fast-selling cancer drugs boosted first-quarter sales at Roche Holding AG by 16 percent to 11.4 billion Swiss francs , the Swiss drugmaker said, raising its outlook for the full year.
Sales in its all-important pharmaceutical division rose by 18 percent to 9.14 billion francs, the world's largest maker of cancer drugs said on Wednesday, driven by new uses of its top cancer treatments Avastin, Herceptin, Xeloda and MabThera.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment